TOP > 外国特許検索 > METHOD AND KIT FOR EVALUATING PROGNOSIS, DISTANT RECURRENCE RISK AND INVASION OF GLIOMA, AND PHARMACEUTICAL COMPOSITION FOR TREATING GLIOMA

METHOD AND KIT FOR EVALUATING PROGNOSIS, DISTANT RECURRENCE RISK AND INVASION OF GLIOMA, AND PHARMACEUTICAL COMPOSITION FOR TREATING GLIOMA

外国特許コード F170009258
掲載日 2017年10月24日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP072204
国際公開番号 WO 2017022634
国際出願日 平成28年7月28日(2016.7.28)
国際公開日 平成29年2月9日(2017.2.9)
優先権データ
  • 特願2015-151838 (2015.7.31) JP
発明の名称 (英語) METHOD AND KIT FOR EVALUATING PROGNOSIS, DISTANT RECURRENCE RISK AND INVASION OF GLIOMA, AND PHARMACEUTICAL COMPOSITION FOR TREATING GLIOMA
発明の概要(英語) [Problem] The present invention addresses the problem of providing a novel biomarker which makes it possible to find the prognosis of glioma, the risk of distant recurrence of glioma, the invasion ability of glioma cells and the like and also makes it possible to detect the prognosis, the risk, the invasion ability or the like in an earlier stage of a therapy of glioma.
[Solution] The present invention relates to a method for evaluating the prognosis of glioma, said method comprising the steps of: detecting ACTC1 protein and/or mRNA encoding the protein in a glioma-containing sample collected from a patient; and determining that the prognosis of the glioma is poor when the ACTC1 protein and/or the mRNA encoding the protein is detected in the aforementioned step. According to the present invention, the prognosis of glioma, the risk of distant recurrence of glioma, the invasion ability and the like can be evaluated using a novel biomarker, i.e., ACTC1 protein and/or mRNA encoding the protein.
従来技術、競合技術の概要(英語) BACKGROUND ART
Glioma a malignant tumor occurring in the brain, account for many of the brain. World Health Organization (WHO) glioma is 4 according to the criteria of the two grades (grade I-IV) is classified. Grade III and IV glioma is referred to as a high-grade gliomas, high proliferative potential, with the invasive potential. Of high-grade gliomas, the highest degree the most malignant, is classified as glioblastoma grade IV (glioblastoma multiform, GBM) and, it is approximately 10% year survival is only 5.
Is glioma, brain tumor cells infiltrate into normal tissue as sinks into the boundary is blurred, depending on the position of the tumors by surgery for harvesting the difficulty, it is difficult to achieve complete resection by surgery or disease. Therefore, glioma, glioblastoma and in particular for treatment of high grade glioma and, by surgery after removing the tumor as much as possible, in order to prevent or delay recurrence of radiotherapy and chemotherapy with temozolomide is typical. However, these treatments were performed properly even when, because of its high glioblastoma the invasive potential of the distal portion away from the primary site recurrence at the easily occurs frequently, this is one of the causes of poor prognosis of glioblastoma respectively. Therefore, high-grade glioma is glioma and further information regarding whether or not a glioblastoma, glioma and further high-grade glioma and glioblastoma is likely to progress to the information related to whether or not, of use in the course of the treatment of glioma patients is beneficial.
As a factor associated with the prognosis of a glioma, a number of genetic factors, such as PTEN, p16INK4a deletions, MDM2, EGFR, TP53 and the like have been reported. IDH mutations are particularly good prognosis factor and high-grade gliomas, of the response of the MGMT promoter methylation cyclophosphazdde is considered to be a predictor. These other, and is being investigated further glioma marker (such as for example non-patent document 1).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • SAPPORO MEDICAL UNIVERSITY
  • 発明者(英語)
  • HONMOU Osamu
  • WANIBUCHI Masahiko
  • OHTAKI Shunya
  • SASAKI Masanori
  • SASAKI Yuko
  • MIKUNI Nobuhiro
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG

PAGE TOP

close
close
close
close
close
close